Qingdao Haier Biomedical (SHA:688139) terminated its plan to absorb and merge with subsidiary Shanghai RAAS Blood Products (SHE:002252).
The company cited the complexity of the transaction's structure for the termination, according to a Tuesday filing with the Shanghai bourse.
Shares of the biomedical cold chain storage manufacturer were down 11% in recent trade, while shares of Shanghai RAAS fell almost 6%.